The German couple, who is of Turkish descent, is now the most likely to be the first to bring the coronavirus vaccine to market, which would be a unique achievement. Ugur Sahin with 55 years old, a native of Turkey, is the head of a German research and pharmaceutical company known as BioNTech. He co-founded it with his wife Özlem Türeci, 53, who is also on the board of its board, along with his former professor Professor Christoph Huber, an expert in cancer medicine from Austria (Austria).
What’s so significant about a goat’s head? ”
BioNTech and the US-based Pfizer pharmaceutical company announced on Monday that their vaccine has a 90% chance of preventing Covid-19 infection, according to a study from a third-party study.
It is one of the 11 vaccines in the world that is currently in the final stages of testing, which is being developed by other industries and research institutes. Never before in the world has vaccination been as fast as it is now.
Usually, the research and testing of the vaccines depend on whether they work for seven or eight years. The Covid-19 vaccine team at the BioNTech company has been dubbed the "Project Lightspeed", as a way to say that it is operating at a very high speed as light.
Who made these?
Professor Sahin and Dr Türeci founded BioNTech (Photo from Internet)
Professor Sahin and Dr Türeci founded BioNTech in 2008 in the city of Mainz in western Germany. Both were born to immigrant parents from Turkey. Ugur Sahin was four years old when he arrived in Germany with his mother where he met his father, who worked in a Ford car factory in Cologne.
Ugur Sahin, who studied medicine at the University of Cologne, says he often stayed in the 'laboratory' until late at night before he rode his bicycle home. Even today he goes to work and rides his bicycle.
Matthias Kromayer, from MIG AG who has invested in BioNTech since its inception, said: "He has never changed at all in terms of amazing humility and good manners." Before the coronavirus epidemic began, BioNTech was researching cancer drugs for each person in terms of their body's immune system, but so far no cure has yet reached the approval stage.
In his upbringing, lemzlem Türeci followed his father closely, who was a doctor - he had a clinic at home. "I could not have imagined that there was any other profession I could have undertaken even when I was a teenage girl," Ms Türeci's words were repeated.
Now the value of their company on the New York-based Nasdaq financial and stock market has fluctuated to $ 21 billion, up from $ 4.6 billion it was last year. Professor Sahin, the head of the company, which still holds an 18% stake, is now among the top 10 richest people in Germany. His wife is the chief physician at the centre.
They married in 2002 when Professor Sahin was working at Mainz University Hospital. Even on their wedding day, Professor Sahin spent some time in a ‘laboratory’ doing research and is still teaching at the University.
It was in 2001 that they became entrepreneurs in the field of pharmaceuticals, founded Ganymed Pharmaceuticals, a company that manufactures drugs that help the body fight cancer. They sold it in 2016 for 422 million euros (more than 487Frw).
information from the BBC website , BioNTech employs more than 1,300 workers from more than 60 countries, more than half of whom are women, according to the German newspaper Deutsche Welle. In the first month, after reading about coronavirus in the medical journal The Lancet, Professor Sahin immediately noticed how fast it was spreading.
So after learning about coronavirus statistics, he immediately hired more than 400 staff to make the coronavirus vaccine. "The value of my share is not what I am worried about," he told the German news website Wirtschaftswoche.
"We wanted to build a centre that was like a research centre and make medicine like an Amgen or Genentech company. We want to set a long-term value. That's what I'm concerned about," he said.